Astellas

News

Padcev/Keytruda scores again in early bladder cancer

Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as perioperative therapy for muscle-invasive bladder cancer.

News

EMA starts review of 'transformative' bladder cancer therapy

The EMA has started a review of a regimen based on Pfizer/Astellas' Padcev and MSD's Keytruda that is described as a game-changer for bladder cancer.

Oncology

Interview at ESMO 2025 with Tadaaki Taniguchi

ESMO25: On next-generation bispecifics, with Tadaaki Taniguc...

At ESMO 2025 in Berlin, pharmaphorum spoke with Tadaaki Taniguchi, Chief Research & Development Officer at Astellas.

News

Astellas suffers pancreatic cancer failure with Vyloy

Astellas' effort to expand the reach of its first-in-class claudin 18.2 drug Vyloy into pancreatic cancer has had a major setback.

News

Woman at work suffering a symptom of menopause

Poll paints picture of menopause discrimination at work

A survey of women across six countries has found more than a third have experienced some kind of negative impact in the workplace due to menopause.

News

NICE backs bladder cancer duo that can double survival

A new treatment regimen for advanced bladder cancer combining MSD's Keytruda with Astellas' Padcev has been given the green light for NHS use.

Padcev/Keytruda scores again in early bladder cancer

EMA starts review of 'transformative' bladder cancer therapy

ESMO25: On next-generation bispecifics, with Tadaaki Taniguc...

Astellas suffers pancreatic cancer failure with Vyloy

Poll paints picture of menopause discrimination at work

NICE backs bladder cancer duo that can double survival

On genomics, NGS, and doing much more good than bad, with Ma...

How to meet your physicians where they are online

Astellas

Editor's Picks